JS002

DRUG6 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd.

Conditions

Health VolunteerHypercholesterolemiaHyperlipemiaPrimary Hypercholesterolaemia and Mixed Dyslipidemia

Phase 1

A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

CompletedNCT04197817

Shanghai Junshi Bioscience Co., Ltd.Hypercholesterolemia

Start: 2017-12-11End: 2018-08-14Updated: 2019-12-13

A Pharmacokinetic Study of JS002 in Healthy Subjects

CompletedNCT05859529

Shanghai Junshi Bioscience Co., Ltd.Health Volunteer

Start: 2023-05-30End: 2023-09-11Updated: 2024-09-05

Phase 2

To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

CompletedNCT04515927

Shanghai Junshi Bioscience Co., Ltd.Hyperlipemia

Start: 2020-08-17End: 2022-07-29Updated: 2024-07-24

Phase 3

The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

CompletedNCT04781114

Shanghai Junshi Bioscience Co., Ltd.Hyperlipemia

Start: 2020-12-23End: 2023-01-16Updated: 2023-04-19

The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

CompletedNCT05532800

Shanghai Junshi Bioscience Co., Ltd.Hyperlipemia

Start: 2022-02-28End: 2023-02-09Updated: 2023-03-15

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

RecruitingNCT05621070

Shanghai Junshi Bioscience Co., Ltd.Primary Hypercholesterolaemia and Mixed Dyslipidemia

Start: 2023-02-03End: 2024-09-30Target: 582Updated: 2024-09-19

Related Papers

Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial.

2025-06-161 citations

Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia

Journal of the American Heart Association2024-05-319 citations